Bio-X
Showing 41-50 of 69 Results
-
Miriam B. Goodman
Mrs. George A. Winzer Professor of Cell Biology
Current Research and Scholarly InterestsWe study the molecular events that give rise to the sensation of touch and chemical stressors that compromise touch sensation in C. elegans. To do this, we use a combination of quantitative behavioral analysis, genetics, in vivo electrophysiology, and heterologous expression of ion channels. We collaborate with physicists and other physiologist to expand our experimental research.
-
Stuart Goodman, MD, PhD
The Robert L. and Mary Ellenburg Professor of Surgery and Professor, by courtesy, of Bioengineering
On Partial Leave from 09/01/2024 To 08/31/2025Current Research and Scholarly InterestsAs an academic orthopaedic surgeon, my interests center on adult reconstructive surgery, arthritis surgery, joint replacement, biomaterials, biocompatibility, tissue engineering, mesenchymal stem cells. Collaborative clinical, applied and basic research studies are ongoing.
-
Kenneth Goodson
Senior Associate Dean for Research and Faculty Affairs, Davies Family Provostial Professor, and Professor, by courtesy, of Materials Science and Engineering
Current Research and Scholarly InterestsProf. Goodson’s Nanoheat Lab studies heat transfer in electronic nanostructures, microfluidic heat sinks, and packaging, focussing on basic transport physics and practical impact for industry. We work closely with companies on novel cooling and packaging strategies for power devices, portables, ASICs, & data centers. At present, sponsors and collaborators include ARPA-E, the NSF POETS Center, SRC ASCENT, Google, Intel, Toyota, Ford, among others.
-
William Rowland Goodyer, MD/PhD
Assistant Professor of Pediatrics (Cardiology)
BioDr. Goodyer is a physician scientist who specializes in Pediatric Cardiology and Electrophysiology. Will graduated from McGill University (Montreal, Canada) with a BSc in Biology prior to completing his graduate studies at Stanford University in the Medical Scientist Training Program (MSTP). He subsequently completed residency training in Pediatrics at Boston Children’s Hospital before returning to Stanford to complete a fellowship in Pediatric Cardiology and advanced fellowship in Pediatric Electrophysiology. He additionally performed a postdoctoral fellowship in the Sean Wu laboratory at the Stanford Cardiovascular Institute where he developed the first comprehensive single-cell gene atlas of the entire murine cardiac conduction system (CCS) as well as pioneered the generation of optical imaging agents for the real-time visualization of the CCS to help prevent accidental surgical damage during heart surgeries. Will's lab (www.goodyerlab.com) focuses on basic science advances aimed at the improved diagnosis and treatment of cardiac arrhythmias.
-
Deborah M Gordon
Paul S. and Billie Achilles Professor of Environmental Biology
Current Research and Scholarly InterestsProfessor Deborah M Gordon studies the evolutionary ecology of collective behavior. Ant colonies operate without central control, using local interactions to regulate colony behavior.
-
Jorg Goronzy
Professor of Medicine (Immunology and Rheumatology), Emeritus
Current Research and Scholarly InterestsT cell homeostasis and function with age
-
Ian Gotlib
David Starr Jordan Professor
Current Research and Scholarly InterestsCurrent interests include social, cognitive, and biological factors in affective disorders; neural and cognitive processing of emotional stimuli and reward by depressed persons; behavioral activation and anhedonia in depression; social, emotional, and biological risk factors for depression in children.
-
Or Gozani
Dr. Morris Herzstein Professor
Current Research and Scholarly InterestsWe study the molecular mechanisms by which chromatin-signaling networks effect nuclear and epigenetic programs, and how dysregulation of these pathways leads to disease. Our work centers on the biology of lysine methylation, a principal chromatin-regulatory mechanism that directs epigenetic processes. We study how lysine methylation events are generated, sensed, and transduced, and how these chemical marks integrate with other nuclear signaling systems to govern diverse cellular functions.
-
Edward Graves
Associate Professor of Radiation Oncology (Radiation Physics) and, by courtesy, of Radiology (Molecular Imaging Program at Stanford)
Current Research and Scholarly InterestsApplications of molecular imaging in radiation therapy, development of hypoxia and radiosensitivity imaging techniques, small animal image-guided conformal radiotherapy, image processing and analysis.
-
Nathanael S. Gray
Krishnan-Shah Family Professor
BioNathanael Gray is the Krishnan-Shah Family Professor of Chemical and Systems Biology at Stanford, Co-Director of Cancer Drug Discovery Co-Leader of the Cancer Therapeutics Research Program, Member of Chem-H, and Program Leader for Small Molecule Drug Discovery for the Innovative Medicines Accelerator (IMA). His research utilizes the tools of synthetic chemistry, protein biochemistry, and cancer biology to discover and validate new strategies for the inhibition of anti-cancer targets. Dr. Gray’s research has had broad impact in the areas of kinase inhibitor design and in circumventing drug resistance.
Dr. Gray received his PhD in organic chemistry from the University of California at Berkeley in 1999 after receiving his BS degree with the highest honor award from the same institution in 1995. After completing his PhD, Dr. Gray was recruited to the newly established Genomics Institute of the Novartis Research Foundation (GNF) in San Diego, California. During his six year stay at GNF, Dr. Gray became the director of biological chemistry where he supervised a group of over fifty researchers integrating chemical, biological and pharmacological approaches towards the development of new experimental drugs. Some of the notable accomplishments of Dr. Gray’s team at GNF include: discovery of the first allosteric inhibitors of wild-type and mutant forms of BCR-ABL which resulted in clinical development of ABL001; discovery of the first selective inhibitors of the Anaplastic Lymphoma Kinase (ALK), an achievement that led to the development of now FDA-approved drugs such as ceritinib (LDK378) for the treatment of EML4-ALK expressing non-small cell lung cancer (NSCLC); and discovery that sphingosine-1-phosphate receptor-1 (S1P1) is the pharmacologically relevant target of the immunosuppressant drug Fingomilod (FTY720) followed by the development of Siponimod (BAF312), which is currently used for the treatment of multiple sclerosis.
In 2006, Dr. Gray returned to academia as a faculty member at the Dana Farber Cancer Institute and Harvard Medical School in Boston. There, he has established a discovery chemistry group that focuses on developing first-in-class inhibitors for newly emerging biological targets, including resistant alleles of existing targets, as well as inhibitors of well-validated targets, such as Her3 and RAS, that have previously been considered recalcitrant to small molecule drug development. Dr. Gray’s team developed covalent inhibitors of the T790M mutant of EGFR inspired the development of Osimertinib (AZD9291), now FDA approved for treatment of patients with relapsed lung cancer due to resistance to first generation EGFR inhibitors. Dr. Gray has also developed structure-based, generalized approaches for designing drugs to overcome one of the most common mechanisms of resistance observed against most kinase inhibitor drugs, mutation of the so-called "gatekeeper" residue, which has been observed in resistance to drugs targeting BCR-ABL, c-KIT and PDGFR.
In 2021, Dr. Gray joined Stanford University where he has joined the Stanford Cancer Institute, Chem-H and the Innovative Medicines Accelerator (IMA) to spur the development of prototype drugs.
These contributions have been recognized through numerous awards including the National Science Foundation’s Career award in 2007, the Damon Runyon Foundation Innovator award in 2008, the American Association for Cancer Research for Team Science in 2010 and for Outstanding Achievement in 2011 and the American Chemical Society award for Biological Chemistry in 2011, and the Nancy Lurie Marks endowed professorship in 2015 and the Paul Marks Prize in 2019, and the Hope Funds for Cancer Research in 2023.